Jiae Kim

Dr. Jiae Kim

Asan Medical Center, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JKJiae Kim
Jiae Kim
YKYe Young Kim
Ye Young Kim
SLSeung Hak Lee
Seung Hak Lee
CJChul Jung
Chul Jung
MKMi Hee Kim
Mi Hee Kim
DKDae Yul Kim
Dae Yul Kim
The mechanism of the neuroprotective effect of the macrophage migration inhibitory factor (MIF) in vivo is unclear. We investigated whether the MIF promotes neurological recovery in an in vivo mouse model of ischemic stroke. Transient middle cerebral artery occlusion (MCAO) surgery was performed to make ischemic stroke mouse model. Male mice were allocated to a sham vehicle, a sham MIF, a middle cerebral artery occlusion (MCAO) vehicle, and MCAO+MIF groups. Transient MCAO (tMCAO) was performed in the MCAO groups, and the vehicle and the MIF were administered via the intracerebroventricular route. We evaluated the neurological functional scale, the rotarod test, and T2-weighted magnetic resonance imaging. The expression level of the microtubule-associated protein 2 (MAP2), Bcl2, and the brain-derived neurotrophic factor (BDNF) were further measured by Western blot assay. The Garcia test was significantly higher in the MCAO+MIF group than in the MCAO+vehicle group. The MCAO+MIF group exhibited significantly better performance on the rotarod test than the MCAO+vehicle group, which further had a significantly reduced total infarct volume on T2-weighted MRI imaging than the MCAO vehicle group. Expression levels of BDNF, and MAP2 tended to be higher in the MCAO+MIF group than in the MCAO+vehicle group. The MIF exerts a neuroprotective effect in an in vivo ischemic stroke model. The MIF facilitates neurological recovery and protects brain tissue from ischemic injury, indicating a possibility of future novel therapeutic agents for stroke patients.

23 February 2021 in Brain Sciences
Verified
Journal Article
Open access
PDF file
CJChul Jung
Chul Jung
MKMi Hee Kim
Mi Hee Kim
YKYe Yeong Kim
Ye Yeong Kim
JKJiae Kim
Jiae Kim
EKEun Jae Ko
Eun Jae Ko
DKDae Yul Kim
Dae Yul Kim
Macrophage migration inhibitory factor (MIF) exerts neuroprotective effects against cerebral ischemia/reperfusion injury by inhibiting neuronal apoptosis and inducing the expression of brain-derived neurotrophic factor (BDNF). However, the optimal administration conditions of MIF are currently unknown. Here, we aimed to identify these conditions in an in vitro model. To determine the optimal concentration of MIF, human neuroblastoma cells were assigned to one of seven groups: control, oxygen and glucose deprivation/reperfusion (OGD/R), and OGD/R with different concentrations (1, 10, 30, 60, and 100 ng/mL) of MIF. Six groups were studied to investigate the optimal administration time: control, OGD/R, and OGD/R with MIF administered at different times (pre-OGD, OGD-treat, post-OGD, and whole-processing). Water-soluble tetrazolium salt-1 assay, Western blot analysis, and immunocytochemistry were used to analyze cell viability and protein expression. We found that 60 ng/mL was the optimal concentration of MIF. However, the effects of administration time were not significant; MIF elicited similar neuroprotective effects regardless of administration time. These findings correlated with the expression of BDNF and apoptosis-related proteins. This study provides detailed information on MIF administration, which offers a foundation for future in vivo studies and translation into novel therapeutic strategies for ischemic stroke.

23 September 2022 in Medicine
Verified
Journal Article
Open access
JKJiae Kim
Jiae Kim
MCMin Ho Chun
Min Ho Chun
JLJunekyung Lee
Junekyung Lee
JKJun Won Kim
Jun Won Kim
JLJi Yeon Bs Lee
Ji Yeon Bs Lee
Objective: This study is aimed to compare the effect of robot-assisted gait training when the intensity is controlled using patients’ biometric data to when controlled by therapist’s subjective judgment. Design: This is non-blinded, prospective, randomized controlled study. Patients were randomly assigned to one of two groups. In biometric data control group, exercise intensity was controlled through the patient’s heart rate or rating of perceived exertion (RPE). The intensity was raised to the next level when the patient’s heart rate reserve was less than 40 percent or the RPE was less than 12 points. The exercise intensity of the therapist control group was adjusted according to the judgement of a therapist. All patients were instructed to perform robot (Morning Walk®)-assisted 20-minute gait training session five times a week during 3 weeks. The primary outcome was functional ambulation category (FAC). The secondary outcomes were modified Barthel index (MBI), Berg balance scale (BBS), timed up and go test (TUG) and 10-meter walk test (10MWT) The outcomes were evaluated at baseline and after 3-week gait training. Results: A total of 55 patients with stroke were enrolled. After robotic rehabilitation, the primary outcome, FAC improved significantly (P < .05) in both groups. Also, secondary outcomes, including MBI, BBS, TUG, 10MWT, showed significant improvement (P < .05) in all groups. In addition, when comparing the functional change from baseline to week 3 between the two groups, there was no statistically significant difference in FAC (P > .05). The difference of baseline and week 3 of secondary outcome measure, MBI, BBS, TUG, 10MWT, showed no significant difference (P > .05). Conclusion: In conclusion, when the robot intensity was adjusted using the patient’s heart rate or RPE, the treatment effect has no significant difference to when adjusting the intensity according to the know-how of the therapist.

30 April 2023 in Journal of Electrodiagnosis and Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
JKJiae Kim
Jiae Kim
DYDong hyun Ye
Dong hyun Ye
HSHee Tae Shin
Hee Tae Shin
SLSeung Hak Lee
Seung Hak Lee
EKEun Jae Ko
Eun Jae Ko
Lamin A (LMNA)-related congenital muscular dystrophy usually presents with hypotonia and severe axial muscle weakness in early infancy. We report a patient who initially presented with torticollis but was finally diagnosed with LMNA-related congenital muscular dystrophy. A 7-month-old infant presented to the outpatient clinic with a chief complaint of torticollis. During a thorough physical examination, axial muscle weakness and gross motor delay were noted, and she was admitted to the pediatric rehabilitation department for further evaluation. The serum creatine kinase level was elevated, and electromyography demonstrated the possibility of hereditary myopathy or a motor neuron disorder. A gene study was conducted, and it showed a c.745C>T (p.Arg249Trp) mutation in the LMNA gene, which is known to cause congenital muscular dystrophy in rare cases. Since there are few reports describing nerve conduction and electromyography studies in patients with LMNA-related congenital muscular dystrophy, this case is meaningful.

28 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
JCJong Yoon Chang
Jong Yoon Chang
MKMi Hee Kim
Mi Hee Kim
JKJiae Kim
Jiae Kim
CBCho Rong Bae
Cho Rong Bae
EKEun Jae Ko
Eun Jae Ko
DKDae Yul Kim
Dae Yul Kim
Background Electrical stimulation (ES) has emerged as a promising non-pharmacological approach for promoting neuronal survival, regeneration, and neuroplasticity. We aimed to determine whether applying ES to brain cells promotes cell viability and how it impacts the expression of brain-derived neurotrophic factor (BDNF), relaxin-3, B-cell lymphoma-2 (bcl-2), and caspase-3. The ultimate objective is to facilitate future in vivo studies.Materials and Methods We used SH-SY5Y cells derived from the human neuroblastoma cell line. Cells were categorized into four groups: control, control with ES, oxygen and glucose deprivation/reperfusion (OGD/R), and OGD/R with ES. ES was administered at an intensity of 100 mV/mm for one hour per day. Cell viability was assessed using the WST-1 assay, while protein expression was analyzed by Western blotting and immunocytochemistry.Results ES enhanced cell viability in SH-SY5Y cells. Furthermore, the expression of BDNF, a protein known for its neuroprotective effects, was increased in the OGD/R group that received ES. Additionally, in the electrically stimulated groups, expression levels of relaxin-3, a neuropeptide involved in regulating key functions including arousal and bcl-2, an anti-apoptotic marker, were both increased. However, caspase-3, an apoptosis-related marker, decreased following ES in both the control and OGD/R groups.Conclusions This study demonstrated that direct current ES enhances cell survival and modulates key neuroprotective biomarkers in SH-SY5Y cells under ischemic-like conditions. These findings provide evidence supporting the therapeutic potential of ES and may serve as a valuable basis for future in vivo studies aimed at exploring its clinical applicability in neuroprotection.